# Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach

> **NCT07178340** · PHASE2 · RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 30 (estimated)

## Conditions studied

- Hepatoid Adenocarcinoma of Stomach

## Interventions

- **DRUG:** Perioperative treatment with albumin-bound paclitaxel, oxaliplatin, tegafur,gimeracil and oteracil porassium capsules and sintilimab.

## Key facts

- **NCT ID:** NCT07178340
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-18
- **Primary completion:** 2027-09-20
- **Final completion:** 2028-09-20
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07178340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07178340, "Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT07178340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*